<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="182688">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716144</url>
  </required_header>
  <id_info>
    <org_study_id>BT0720-201-INT</org_study_id>
    <nct_id>NCT00716144</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Study of the Safety and Efficacy of Oral R115866 and R115866 Placebo in the Treatment of Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible subjects will be randomly assigned to one of three dose regimens of oral R115866 or
      placebo for the treatment of severe plaque psoriasis for 12 twelve weeks. The safety and
      efficacy of R115866 will be evaluated during the treatment period and the 8-week post
      treatment follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI75 success at Visit 6</measure>
    <time_frame>Visit 6 (post 12 weeks on treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PASI50</measure>
    <time_frame>each post-baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment</measure>
    <time_frame>each post-baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI75</measure>
    <time_frame>each post-baseline visit except Visit 6</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Talarozole 0.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Talarozole 1.0 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Talarozole 2.0 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Talarozole matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talarozole</intervention_name>
    <description>Oral Capsule Once Daily</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>R115866</other_name>
    <other_name>Rambazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plaque Psoriasis with PASI greater than or equal to 10

          -  Male or a female who was NOT of childbearing potential (i.e., post- menopausal for
             greater than 12 months or had a complete hysterectomy);

        Exclusion Criteria:

          -  Spontaneously improving or rapidly deteriorating plaque psoriasis

          -  Guttate, pustular, erythrodermic, or other non-plaque form of psoriasis

          -  Subject was under treatment for a heart disorder or had a history of cardiovascular
             disease (excluding effectively controlled hypertension)

          -  Any acute psychiatric condition, including an increased risk for suicide attempt,
             based on medical and psychiatric history

          -  Previous use of a psoriasis vaccine or had participated in an investigational study
             of a psoriasis vaccine

          -  Previous use of systemic immunomodulatory therapy known to affect psoriasis and to
             typically decrease immune cell populations

          -  Previous use of any systemic immunomodulatory therapy known to affect psoriasis and
             NOT typically to decrease immune cell populations

          -  Previous use of any photo-therapy (including laser), photo-chemotherapy, or systemic
             psoriasis therapy (such as systemic corticosteroids, methotrexate, retinoids, or
             cyclosporine) within the previous four weeks

          -  Pregnant or a nursing mother

          -  Significant coexisting hepatic, renal, or bone marrow disease, hyperlipidemia,
             chronic pancreatitis, osteoporosis, cancer (except non-melanoma skin cancer), a
             positive test for human immunodeficiency virus (HIV), a history indicating adrenal
             cortex dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher EM Griffiths, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Hospital, University of Manchester, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Studienzentrum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universit√§t</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Salzwedel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Infirmary Victoria Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Medical Preventive Institute</name>
      <address>
        <city>Korolev</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution of Public Health Services</name>
      <address>
        <city>Lipetsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution of Public Health</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Establishment of Higher Professional Education Russian State Medical University of Roszdrav</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution</name>
      <address>
        <city>Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Establishment of Public Health Services</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Institution of Higher Professional Education Military Medical Academy</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institute of Public Health Service</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Out-Patient Clinic</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amersham Hospital</name>
      <address>
        <city>Amersham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Eliot Hospital</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Hospital, University of Manchester</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>September 23, 2011</lastchanged_date>
  <firstreceived_date>July 15, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>R 115866</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
